Devonian Health Group announces the completion of the second tranche of its previously announced private placement and provides an update.
PRESS RELEASE For immediate release Devonian Health Group announces the completion of the second tranche of its previously announced private placement and provides an update. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED...
Devonian Health Group provides an update on its previously announced private placement.
PRESS RELEASE For immediate release NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES. Devonian Health Group provides an update on its previously announced private placement. Quebec, Quebec – August 06, 2018 – Devonian...
Devonian Health Group Announces issuance of European Patent for its Purgenesis™ anti-aging treatment.
PRESS RELEASE For immediate release Devonian Health Group Announces issuance of European Patent for its Purgenesis™ anti-aging treatment. Quebec, Quebec – July 31st, 2018 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage...
Devonian Health Group announces Non-Brokered Financing by way of a private placement of Convertible Debenture.
PRESS RELEASE For immediate release NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN THE UNITED STATES. Devonian Health Group announces Non-Brokered Financing by way of a private placement of Convertible Debenture. Aspri Pharma Canada Inc....
Devonian Healthcare Group Reports its First ever Revenues: Key Financial Results for Quarter Ended April 30th, 2018
PRESS RELEASE For immediate release Devonian Healthcare Group Reports its First ever Revenues: Key Financial Results for Quarter Ended April 30th, 2018 Quebec, Quebec – July 18, 2018 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a...
Devonian Announces Grant of Options
PRESS RELEASE For immediate release Devonian Announces Grant of Options. Quebec, Quebec - June 29th, 2018 – Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXv: GSD) announces that the Board of Directors has approved the grant of options (the...
Devonian Announces the Signing of a Non-Binding Letter of Intent with Folia Biotech to develop FB-631 in cancer immunotherapy.
PRESS RELEASE For immediate release Devonian Announces the Signing of a Non-Binding Letter of Intent with Folia Biotech to develop FB-631 in cancer immunotherapy. Quebec, Quebec - June 28th, 2018 – Devonian Health Group Inc. ("Devonian" or the "Corporation")...
Devonian Health Group Announces issuance of United States Patent for its Purgenesis™ anti-aging treatment.
PRESS RELEASE For immediate release Devonian Health Group Announces issuance of United States Patent for its Purgenesis™ anti-aging treatment. Quebec, June 27th, 2018 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD)Devonian Health Group Inc....
Devonian Health Group announces the commercial launch of the Purgenesis™ Anti-aging treatment at the Canadian Dermatology Association’s annual conference
PRESS RELEASE For immediate release Devonian Health Group announces the commercial launch of the Purgenesis™ Anti-aging treatment at the Canadian Dermatology Association’s annual conference. First launch of the Purgenesis™ skin care line First and only product...
Purgenesis™: Commercializing a Skin-Care Revolution
READ MORE